Patients who have CLL cells with high levels of MMP-9 have been found to experience more aggressive disease progression and less favorable clinical outcomes compared to patients who have CLL cells with low-to-negligible MMP-9 [4, 6]. This evidence concerns the gene MMP9 and B-cell chronic lymphocytic leukemia.